AR109355A2 - Moléculas de unión al receptor ox40 humano - Google Patents
Moléculas de unión al receptor ox40 humanoInfo
- Publication number
- AR109355A2 AR109355A2 ARP170102289A ARP170102289A AR109355A2 AR 109355 A2 AR109355 A2 AR 109355A2 AR P170102289 A ARP170102289 A AR P170102289A AR P170102289 A ARP170102289 A AR P170102289A AR 109355 A2 AR109355 A2 AR 109355A2
- Authority
- AR
- Argentina
- Prior art keywords
- molecules
- binding molecules
- binding
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente descripción proporciona moléculas de unión aisladas que se unen al OX40R humano, las moléculas de ácido nucleico que codifican la secuencia de aminoácidos de las moléculas de unión, los vectores que comprenden las moléculas de ácido nucleicos, las células huésped que contienen los vectores, los métodos de obtención de las moléculas de unión, las composiciones farmacéuticas que contienen las moléculas de unión, y los métodos de uso de las moléculas de unión o composiciones. Reivindicación 1: Una molécula de unión aislada que compite por la unión a OX40R humano con un anticuerpo que comprende: (a) una región variable de cadena pesada que comprende la secuencia de aminoácidos de la SEC ID Nº 7; y (b) una región variable de cadena liviana que comprende la secuencia de aminoácidos de la SEC ID Nº 8.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1394707P | 2007-12-14 | 2007-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109355A2 true AR109355A2 (es) | 2018-11-21 |
Family
ID=40552119
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105418A AR069681A1 (es) | 2007-12-14 | 2008-12-12 | Moleculas de union al receptor ox40 humano |
| ARP170102289A AR109355A2 (es) | 2007-12-14 | 2017-08-16 | Moléculas de unión al receptor ox40 humano |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105418A AR069681A1 (es) | 2007-12-14 | 2008-12-12 | Moleculas de union al receptor ox40 humano |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US7960515B2 (es) |
| EP (4) | EP2242771B1 (es) |
| JP (4) | JP5761997B2 (es) |
| KR (2) | KR101577843B1 (es) |
| CN (1) | CN101918447B (es) |
| AR (2) | AR069681A1 (es) |
| AU (1) | AU2008338591B8 (es) |
| BR (1) | BRPI0820875B1 (es) |
| CA (2) | CA2707773C (es) |
| CL (1) | CL2008003706A1 (es) |
| CO (1) | CO6280541A2 (es) |
| DK (3) | DK2594590T3 (es) |
| ES (3) | ES2425269T3 (es) |
| HR (1) | HRP20141188T8 (es) |
| HU (1) | HUE032735T2 (es) |
| IL (3) | IL206297A (es) |
| MX (1) | MX2010006466A (es) |
| PA (1) | PA8807601A1 (es) |
| PE (1) | PE20091269A1 (es) |
| PH (1) | PH12015500806A1 (es) |
| PL (2) | PL2594590T3 (es) |
| PT (3) | PT2242771E (es) |
| RU (1) | RU2010129045A (es) |
| SG (2) | SG186656A1 (es) |
| SI (3) | SI2594590T1 (es) |
| TW (1) | TW200932268A (es) |
| UY (1) | UY31533A1 (es) |
| WO (1) | WO2009079335A1 (es) |
| ZA (1) | ZA201003579B (es) |
Families Citing this family (168)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2938527B2 (ja) * | 1990-07-30 | 1999-08-23 | 株式会社リコー | 自動原稿給送装置 |
| RU2010129045A (ru) * | 2007-12-14 | 2012-01-20 | Бристоль-Мейерз Сквибб Компани (US) | Связывающие молекулы к рецептору ох40 человека |
| MX2011008697A (es) * | 2009-02-17 | 2011-11-18 | Ucb Pharma Sa | Moleculas de anticuerpos que tiene especificidad para ox40 humano. |
| US20120020960A1 (en) * | 2010-07-26 | 2012-01-26 | Baylor Research Institute | Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer |
| ES2649155T3 (es) | 2010-08-23 | 2018-01-10 | Board Of Regents, The University Of Texas System | Anticuerpos anti-OX40 y procedimientos de uso de los mismos |
| SG10201912092VA (en) | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| BR112014000630A2 (pt) * | 2011-07-11 | 2017-02-14 | Glenmark Pharmaceuticals Sa | anticorpo antagonista ou fragmento do mesmo que se liga a uma ox40 humana, epítopo sobre o domínio extracelular ox40 humano, ácido nucleíco isolado, vetor, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição imunoconjugado, método para tratar um distúrbio mediado por ox40 em um indivíduo, uso de um anticorpo ou fragmento do mesmo, artigo de manufatura, kit e método para classificação in vitro |
| JP6038920B2 (ja) * | 2011-08-23 | 2016-12-07 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 抗ｏｘ４０抗体およびそれを使用する方法 |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| US9758591B2 (en) | 2012-08-24 | 2017-09-12 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis |
| RS58528B1 (sr) | 2012-12-03 | 2019-04-30 | Bristol Myers Squibb Co | Poboljšanje anti-kancerske aktivnosti imunomodulatornih fc fuzionih proteina |
| PL2976361T3 (pl) | 2013-03-18 | 2018-12-31 | Biocerox Products B.V. | Humanizowane przeciwciała anty-CD134 (OX40) i ich zastosowania |
| AU2014304931B2 (en) | 2013-08-08 | 2018-05-10 | Assistance Publique - Hopitaux De Paris | IL-15 and IL-15Raplha sushi domain based modulokines |
| US20150190506A1 (en) | 2013-12-17 | 2015-07-09 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| KR102127408B1 (ko) * | 2014-01-29 | 2020-06-29 | 삼성전자주식회사 | 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체 |
| LT3126394T (lt) * | 2014-03-31 | 2020-01-27 | F. Hoffmann-La Roche Ag | Antikūnai prieš ox40 ir jų naudojimo būdai |
| CN106132439A (zh) | 2014-03-31 | 2016-11-16 | 豪夫迈·罗氏有限公司 | 包含抗血管发生剂和ox40结合激动剂的组合疗法 |
| WO2016007765A1 (en) | 2014-07-11 | 2016-01-14 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of hiv |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| BR112017009159A2 (pt) | 2014-11-03 | 2018-03-06 | Genentech, Inc. | métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40 |
| CA2966523A1 (en) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Assays for detecting t cell immune subsets and methods of use thereof |
| AU2015343494A1 (en) * | 2014-11-06 | 2017-04-27 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and TIGIT inhibitors |
| WO2016081384A1 (en) | 2014-11-17 | 2016-05-26 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| ES2922398T3 (es) * | 2015-01-08 | 2022-09-14 | BioNTech SE | Agentes agonistas de unión al receptor de TNF |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| EP3262073A1 (en) | 2015-02-26 | 2018-01-03 | Merck Patent GmbH | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| AU2016227493B2 (en) | 2015-03-03 | 2022-01-20 | Kymab Limited | Antibodies, uses & methods |
| JP6955445B2 (ja) | 2015-04-07 | 2021-10-27 | ジェネンテック， インコーポレイテッド | アゴニスト性の活性を有する抗原結合複合体及びその使用方法 |
| TWI820377B (zh) | 2015-05-07 | 2023-11-01 | 美商艾吉納斯公司 | 抗ｏｘ４０抗體及其使用方法 |
| GB201509338D0 (en) | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| ES2936317T3 (es) | 2015-05-29 | 2023-03-16 | Bristol Myers Squibb Co | Anticuerpos contra OX40 y usos de los mismos |
| MY193229A (en) | 2015-06-16 | 2022-09-26 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments |
| EP3112381A1 (en) * | 2015-07-01 | 2017-01-04 | FONDAZIONE IRCCS Istituto Nazionale dei Tumori | Bispecific antibodies for use in cancer immunotherapy |
| EP3331919A1 (en) | 2015-08-07 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
| WO2017046746A1 (en) | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist |
| MA42818A (fr) | 2015-09-15 | 2018-07-25 | Gilead Sciences Inc | Modulateurs de récepteurs de type toll pour le traitement du vih |
| RU2761115C1 (ru) | 2015-10-02 | 2021-12-06 | Ф. Хоффманн-Ля Рош Аг | Биспецифические антитела, специфические в отношении костимуляторного tnf-рецептора |
| CN108137684B (zh) * | 2015-10-15 | 2022-03-08 | 苏州丁孚靶点生物技术有限公司 | 抗ox40抗体及其应用 |
| CN108697791B (zh) | 2015-11-03 | 2022-08-23 | 詹森生物科技公司 | 特异性结合pd-1的抗体及其用途 |
| JP2019505476A (ja) | 2015-12-01 | 2019-02-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 組合せ処置およびその方法 |
| US11447557B2 (en) | 2015-12-02 | 2022-09-20 | Agenus Inc. | Antibodies and methods of use thereof |
| ES2863225T3 (es) | 2015-12-03 | 2021-10-11 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos purinos como moduladores del sting |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| MX2018008995A (es) * | 2016-01-25 | 2019-01-10 | Pfizer | Combinacion de un agonista de ox40 y un agonista de 4-1bb para tratar el cancer. |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| EA201892128A1 (ru) | 2016-04-07 | 2019-04-30 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Гетероциклические амиды, полезные в качестве модуляторов |
| ES2921855T3 (es) | 2016-04-07 | 2022-09-01 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas útiles como moduladores de proteínas |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| CA3023157A1 (en) | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| EP3474854A4 (en) | 2016-06-27 | 2020-02-19 | The Regents of The University of California | DRUG ASSOCIATIONS FOR THE TREATMENT OF CANCER |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| RU2745648C2 (ru) * | 2016-07-19 | 2021-03-30 | Ибентрус, Инк. | Биспецифические белки и способы их получения |
| BR112019001136A2 (pt) | 2016-07-20 | 2019-04-30 | Glaxosmithkline Ip Dev Ltd | compostos químicos |
| US11649289B2 (en) | 2016-08-04 | 2023-05-16 | Glaxosmithkline Intellectual Property Development Limited | Anti-ICOS and anti-PD-1 antibody combination therapy |
| WO2018027204A1 (en) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| WO2018031400A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
| KR102587941B1 (ko) | 2016-08-12 | 2023-10-11 | 얀센 바이오테크 인코포레이티드 | 향상된 효능작용 및 이펙터 기능을 갖는 조작된 항체 및 다른 Fc-도메인 함유 분자 |
| US11254738B2 (en) * | 2016-09-07 | 2022-02-22 | The Governing Council Of The University Of Toronto Banting Institute | Synthetic antibodies against VEGF and their uses |
| JP2019530704A (ja) | 2016-10-06 | 2019-10-24 | ファイザー・インコーポレイテッド | がんの処置のためのアベルマブの投与レジメン |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| EP3538152A4 (en) | 2016-11-09 | 2020-09-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES AND METHOD OF USING THEREOF |
| JP2020500878A (ja) | 2016-12-01 | 2020-01-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 併用療法 |
| KR20190090823A (ko) | 2016-12-01 | 2019-08-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 조합 요법 |
| AR110526A1 (es) | 2016-12-15 | 2019-04-10 | Abbvie Biotherapeutics Inc | Anticuerpos anti-ox40 y sus usos en el tratamiento del cáncer |
| AU2017384528A1 (en) | 2016-12-19 | 2019-07-04 | Ichnos Sciences SA | Novel TNFR agonists and uses thereof |
| MX2019007963A (es) | 2017-01-06 | 2019-10-21 | Iovance Biotherapeutics Inc | Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf. |
| US20200062735A1 (en) | 2017-02-27 | 2020-02-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| CN108623686A (zh) | 2017-03-25 | 2018-10-09 | 信达生物制药(苏州)有限公司 | 抗ox40抗体及其用途 |
| TW201919662A (zh) | 2017-06-05 | 2019-06-01 | 美商艾歐凡斯生物治療公司 | 對雙重難治性黑色素瘤使用腫瘤浸潤性淋巴細胞之方法 |
| EP3635011A1 (en) | 2017-06-09 | 2020-04-15 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
| WO2018225034A1 (en) | 2017-06-09 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
| WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
| CN111511762A (zh) | 2017-08-21 | 2020-08-07 | 天演药业公司 | 抗cd137分子及其用途 |
| WO2019040791A1 (en) * | 2017-08-24 | 2019-02-28 | Invenra Inc. | MULTIVALENT AGONIST ANTIBODY CONSTRUCTS AGREEING RECEPTORS |
| US10363272B2 (en) * | 2017-08-31 | 2019-07-30 | Io Therapeutics, Inc. | RAR selective agonists in combination with immune modulators for cancer immunotherapy |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| JP2020536106A (ja) | 2017-10-05 | 2020-12-10 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｈｉｖの処置に有用なインターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質 |
| EP3692034A1 (en) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
| WO2019100023A1 (en) | 2017-11-17 | 2019-05-23 | Iovance Biotherapeutics, Inc. | Til expansion from fine needle aspirates and small biopsies |
| CN112292397B (zh) * | 2017-11-24 | 2023-01-31 | 祐和医药科技(北京)有限公司 | 抗ox40抗体及其用途 |
| US11142579B2 (en) | 2017-12-06 | 2021-10-12 | Sorrento Therapeutics, Inc. | Variant antibodies that bind OX40 |
| EP3731875B1 (en) * | 2017-12-29 | 2023-10-04 | AP Biosciences, Inc. | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| AU2019205823A1 (en) | 2018-01-08 | 2020-07-30 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| JP2021512962A (ja) | 2018-02-13 | 2021-05-20 | アイオバンス バイオセラピューティクス，インコーポレイテッド | アデノシンａ２ａ受容体アンタゴニストによる腫瘍浸潤性リンパ球（ｔｉｌ）の拡大培養並びにｔｉｌ及びアデノシンａ２ａ受容体アンタゴニストの治療的組み合わせ |
| US20210130779A1 (en) | 2018-04-27 | 2021-05-06 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| CA3103040A1 (en) * | 2018-05-11 | 2019-11-14 | Wuxi Biologics (Shanghai) Co., Ltd. | Fully human antibodies against ox40, method for preparing same, and use thereof |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| AU2019274655B2 (en) | 2018-05-23 | 2023-03-09 | Pfizer Inc. | Antibodies specific for GUCY2c and uses thereof |
| TWI793325B (zh) | 2018-05-23 | 2023-02-21 | 美商輝瑞大藥廠 | 對cd3具特異性之抗體及其用途 |
| WO2020011966A1 (en) | 2018-07-12 | 2020-01-16 | F-Star Beta Limited | Antibody molecules that bind cd137 and ox40 |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| US20210277135A1 (en) | 2018-07-13 | 2021-09-09 | Bristol-Myers Squibb Company | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor |
| TW202031273A (zh) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療 |
| JP2022501038A (ja) | 2018-09-20 | 2022-01-06 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 凍結保存腫瘍サンプルからのｔｉｌの拡大培養 |
| EP3877511A1 (en) | 2018-11-05 | 2021-09-15 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
| CN112969469A (zh) | 2018-11-05 | 2021-06-15 | 艾欧凡斯生物治疗公司 | 抗pd-1抗体难治性nsclc患者的治疗 |
| TW202039829A (zh) | 2018-11-05 | 2020-11-01 | 美商艾歐凡斯生物治療公司 | 改善之腫瘤反應性ｔ細胞的選擇 |
| CN113272421A (zh) | 2018-11-05 | 2021-08-17 | 艾欧凡斯生物治疗公司 | 用于产生肿瘤浸润性淋巴细胞的方法及其在免疫疗法中的用途 |
| WO2020097336A1 (en) * | 2018-11-09 | 2020-05-14 | Beth Israel Deaconess Medical Center | Cdcp1-targeted therapies |
| WO2020131547A1 (en) | 2018-12-19 | 2020-06-25 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
| US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
| JP2022523100A (ja) | 2019-02-01 | 2022-04-21 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | ベランタマブマフォドチンおよび抗ｏｘ４０抗体を含むがんの併用治療ならびにその使用および方法 |
| JP2022521355A (ja) | 2019-03-29 | 2022-04-06 | ミスト セラピューティクス リミテッド ライアビリティ カンパニー | Ｔ細胞治療薬を生成するためのエクスビボ方法ならびに関連する組成物および方法 |
| US20220249559A1 (en) | 2019-05-13 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| US20230053328A9 (en) | 2019-05-24 | 2023-02-16 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| AU2020281535A1 (en) | 2019-05-24 | 2022-01-27 | Merck Patent Gmbh | Combination therapies using CDK inhibitors |
| CN110172090B (zh) * | 2019-06-03 | 2020-04-03 | 中山标佳生物科技有限公司 | Cd134单克隆抗体及其制备方法和癌症治疗中的应用 |
| MX2021015651A (es) | 2019-06-26 | 2022-06-14 | Glaxosmithkline Ip Dev Ltd | Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap). |
| US11339159B2 (en) | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| WO2021058711A2 (en) | 2019-09-27 | 2021-04-01 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
| JP2022553389A (ja) | 2019-10-25 | 2022-12-22 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用 |
| AU2020391231A1 (en) | 2019-11-27 | 2022-07-14 | Turnstone Biologics Corp. | Method of producing tumor-reactive T cell composition using modulatory agents |
| CA3161104A1 (en) | 2019-12-11 | 2021-06-17 | Cecile Chartier-Courtaud | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
| JP7369297B2 (ja) | 2019-12-17 | 2023-10-25 | ファイザー・インク | Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用 |
| MX2022007643A (es) | 2019-12-18 | 2022-07-19 | Pfizer | Regimen de tratamiento del cancer una vez por dia con un inhibidor de prmt5. |
| US20230067202A1 (en) | 2020-01-28 | 2023-03-02 | Glaxosmithkline Intellectual Property Development Limited | Combination Treatments and Uses and Methods Thereof |
| EP4110799A1 (en) | 2020-02-27 | 2023-01-04 | Myst Therapeutics, LLC | Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof |
| EP4118105A2 (en) | 2020-03-09 | 2023-01-18 | Pfizer Inc. | Cd80-fc fusion protein and uses thereof |
| EP4130039A4 (en) | 2020-03-23 | 2024-07-31 | Bio Thera Solutions Ltd | DEVELOPMENT AND APPLICATION OF AN IMMUNE CELL ACTIVATOR |
| US20230035733A1 (en) * | 2020-03-26 | 2023-02-02 | Dusa Pharmaceuticals, Inc. | Management of dermal neurofibromatosis lesions |
| EP4136116A4 (en) | 2020-04-17 | 2024-06-19 | Hutchison Medipharma Limited | ANTI-OX40 ANTIBODIES AND ITS USES |
| US20230172987A1 (en) | 2020-05-04 | 2023-06-08 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| TW202208616A (zh) | 2020-05-04 | 2022-03-01 | 美商艾歐凡斯生物治療公司 | 改良之腫瘤反應性ｔ細胞的選擇 |
| CA3182887A1 (en) | 2020-05-13 | 2021-11-18 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
| MX2023000662A (es) | 2020-07-17 | 2023-02-27 | Pfizer | Anticuerpos terapeuticos y sus usos. |
| KR20230069181A (ko) | 2020-09-14 | 2023-05-18 | 화이자 인코포레이티드 | 암 치료를 위한 방법, 요법 및 용도 |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| JP2023546359A (ja) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療 |
| CN114515335A (zh) | 2020-11-19 | 2022-05-20 | 百奥泰生物制药股份有限公司 | 抗ox40抗体在治疗肿瘤或癌症中的应用 |
| US20220168293A1 (en) | 2020-12-02 | 2022-06-02 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
| JP2024501452A (ja) | 2020-12-11 | 2024-01-12 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｂｒａｆ阻害剤及び／またはｍｅｋ阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療 |
| WO2022130206A1 (en) | 2020-12-16 | 2022-06-23 | Pfizer Inc. | TGFβr1 INHIBITOR COMBINATION THERAPIES |
| WO2022133140A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| US20240123067A1 (en) | 2020-12-17 | 2024-04-18 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocyte therapies |
| WO2022153161A1 (en) | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
| WO2022170219A1 (en) | 2021-02-05 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| KR20230154230A (ko) | 2021-03-02 | 2023-11-07 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Dnmt1 억제제로서의 치환된 피리딘 |
| WO2022198055A1 (en) * | 2021-03-19 | 2022-09-22 | KSQ Therapeutics, Inc. | Uses of antagonist, non-depleting ox40 antibodies |
| WO2022208353A1 (en) | 2021-03-31 | 2022-10-06 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins and combinations thereof |
| KR20240037185A (ko) | 2021-04-19 | 2024-03-21 | 이오반스 바이오테라퓨틱스, 인크. | 키메라 공동자극 수용체, 케모카인 수용체, 및 세포 면역치료에서의 이의 용도 |
| WO2022245754A1 (en) | 2021-05-17 | 2022-11-24 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
| TW202327631A (zh) | 2021-07-28 | 2023-07-16 | 美商艾歐凡斯生物治療公司 | 利用腫瘤浸潤性淋巴球療法與ｋｒａｓ抑制劑組合治療癌症患者 |
| EP4404969A1 (en) | 2021-09-24 | 2024-07-31 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
| TW202331735A (zh) | 2021-10-27 | 2023-08-01 | 美商艾歐凡斯生物治療公司 | 協調用於患者特異性免疫療法之細胞之製造的系統及方法 |
| CA3237410A1 (en) | 2021-11-10 | 2023-05-19 | Friedrich Graf Finck VON FINCKENSTEIN | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| AU2022411573A1 (en) | 2021-12-17 | 2024-06-27 | Shanghai Henlius Biologics Co., Ltd. | Anti-ox40 antibodies and methods of use |
| KR20240116755A (ko) | 2021-12-17 | 2024-07-30 | 상하이 헨리우스 바이오테크, 인크. | 항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법 |
| WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
| WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
| WO2023218320A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Anti-lymphotoxin beta receptor antibodies and methods of use thereof |
| WO2023242769A1 (en) | 2022-06-17 | 2023-12-21 | Pfizer Inc. | Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof |
| WO2024003773A1 (en) | 2022-07-01 | 2024-01-04 | Pfizer Inc. | 2,7-naphthyridine compounds as mastl inhibitors |
| WO2024009191A1 (en) | 2022-07-05 | 2024-01-11 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| WO2024074977A1 (en) | 2022-10-04 | 2024-04-11 | Pfizer Inc. | Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds |
| WO2024084364A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Compounds for the treatment of cancer |
| WO2024105563A1 (en) | 2022-11-16 | 2024-05-23 | Pfizer Inc. | Substituted bicyclic pyridone derivatives |
| WO2024151885A1 (en) | 2023-01-13 | 2024-07-18 | Iovance Biotherapeutics, Inc. | Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US191293A (en) | 1877-05-29 | Improvement in car wheels and axles | ||
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| EP1024191B8 (en) | 1991-12-02 | 2008-11-05 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| WO1999042585A1 (en) | 1998-02-24 | 1999-08-26 | Sisters Of Providence In Oregon | Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response |
| CN1328571B (zh) | 1998-12-23 | 2016-08-31 | 辉瑞大药厂 | 抗ctla-4的人单克隆抗体 |
| CN1399645A (zh) | 1999-07-29 | 2003-02-26 | 米德列斯公司 | Her2/neu的人单克隆抗体 |
| MXPA03004793A (es) | 2000-11-30 | 2004-12-03 | Medarex Inc | Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos. |
| OA12589A (en) | 2001-01-05 | 2006-06-08 | Abgenix Inc | Antibodies to insulin-like growth factor i receptor. |
| HUP0302544A3 (en) | 2001-01-09 | 2012-09-28 | Merck Patent Gmbh | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
| CA2447851C (en) | 2001-06-28 | 2012-08-28 | Domantis Limited | Dual-specific ligand and its use |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| WO2003106498A2 (en) * | 2002-06-13 | 2003-12-24 | Crucell Holland, B.V. | Agonistic binding molecules to the human ox40 receptor |
| AU2003244817B2 (en) | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| JP2006523090A (ja) | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体 |
| CA2525120C (en) | 2003-05-14 | 2013-04-30 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
| JP5087274B2 (ja) | 2003-06-30 | 2012-12-05 | ドマンティス リミテッド | ポリペプチド |
| ES2388435T3 (es) * | 2003-12-10 | 2012-10-15 | Medarex, Inc. | Anticuerpos de IP-10 y sus usos |
| EP1846454A2 (en) * | 2004-09-30 | 2007-10-24 | Medarex, Inc. | Human monoclonal antibodies to fc gamma receptor ii (cd32) |
| WO2006050172A2 (en) * | 2004-10-29 | 2006-05-11 | University Of Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
| WO2006055697A2 (en) | 2004-11-17 | 2006-05-26 | Board Of Regents, The University Of Texas System | Cancer immunotherapy incorporating p53 |
| WO2006079372A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| US7189097B2 (en) | 2005-02-11 | 2007-03-13 | Winchester Electronics Corporation | Snap lock connector |
| WO2006129163A1 (en) | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
| JP2006345852A (ja) * | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
| WO2007062093A2 (en) | 2005-11-22 | 2007-05-31 | Incyte Corporation | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor |
| TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| RU2010129045A (ru) * | 2007-12-14 | 2012-01-20 | Бристоль-Мейерз Сквибб Компани (US) | Связывающие молекулы к рецептору ох40 человека |
-
2008
- 2008-12-11 RU RU2010129045/10A patent/RU2010129045A/ru not_active Application Discontinuation
- 2008-12-11 CN CN200880120734.6A patent/CN101918447B/zh active Active
- 2008-12-11 DK DK12195976.1T patent/DK2594590T3/en active
- 2008-12-11 PT PT88625587T patent/PT2242771E/pt unknown
- 2008-12-11 SI SI200831346T patent/SI2594590T1/sl unknown
- 2008-12-11 BR BRPI0820875-1A patent/BRPI0820875B1/pt active IP Right Grant
- 2008-12-11 PT PT121959761T patent/PT2594590E/pt unknown
- 2008-12-11 PT PT141915645T patent/PT2851374T/pt unknown
- 2008-12-11 EP EP08862558.7A patent/EP2242771B1/en active Active
- 2008-12-11 MX MX2010006466A patent/MX2010006466A/es active IP Right Grant
- 2008-12-11 JP JP2010538157A patent/JP5761997B2/ja active Active
- 2008-12-11 EP EP17162625.2A patent/EP3239178A1/en not_active Ceased
- 2008-12-11 DK DK14191564.5T patent/DK2851374T3/en active
- 2008-12-11 CA CA2707773A patent/CA2707773C/en active Active
- 2008-12-11 PL PL12195976T patent/PL2594590T3/pl unknown
- 2008-12-11 PL PL08862558T patent/PL2242771T3/pl unknown
- 2008-12-11 EP EP12195976.1A patent/EP2594590B1/en active Active
- 2008-12-11 SG SG2012092201A patent/SG186656A1/en unknown
- 2008-12-11 US US12/332,944 patent/US7960515B2/en active Active
- 2008-12-11 PE PE2008002051A patent/PE20091269A1/es not_active Application Discontinuation
- 2008-12-11 ES ES08862558T patent/ES2425269T3/es active Active
- 2008-12-11 EP EP14191564.5A patent/EP2851374B1/en active Active
- 2008-12-11 ES ES12195976.1T patent/ES2526887T3/es active Active
- 2008-12-11 AU AU2008338591A patent/AU2008338591B8/en active Active
- 2008-12-11 SI SI200831009T patent/SI2242771T1/sl unknown
- 2008-12-11 HU HUE14191564A patent/HUE032735T2/en unknown
- 2008-12-11 CA CA2949772A patent/CA2949772A1/en not_active Abandoned
- 2008-12-11 KR KR1020107015527A patent/KR101577843B1/ko active IP Right Grant
- 2008-12-11 ES ES14191564.5T patent/ES2628093T3/es active Active
- 2008-12-11 DK DK08862558.7T patent/DK2242771T3/da active
- 2008-12-11 WO PCT/US2008/086417 patent/WO2009079335A1/en active Application Filing
- 2008-12-11 KR KR1020157013715A patent/KR20150061041A/ko not_active Application Discontinuation
- 2008-12-11 SG SG10201604770VA patent/SG10201604770VA/en unknown
- 2008-12-11 SI SI200831814T patent/SI2851374T1/sl unknown
- 2008-12-12 AR ARP080105418A patent/AR069681A1/es active IP Right Grant
- 2008-12-12 PA PA20088807601A patent/PA8807601A1/es unknown
- 2008-12-12 TW TW097148544A patent/TW200932268A/zh unknown
- 2008-12-12 CL CL2008003706A patent/CL2008003706A1/es unknown
- 2008-12-15 UY UY31533A patent/UY31533A1/es active IP Right Grant
-
2010
- 2010-05-20 ZA ZA2010/03579A patent/ZA201003579B/en unknown
- 2010-06-10 IL IL206297A patent/IL206297A/en active IP Right Grant
- 2010-07-14 CO CO10086027A patent/CO6280541A2/es not_active Application Discontinuation
-
2011
- 2011-05-02 US US13/099,196 patent/US8236930B2/en not_active Expired - Fee Related
-
2012
- 2012-05-17 US US13/474,466 patent/US9028824B2/en active Active
-
2014
- 2014-10-31 JP JP2014222800A patent/JP6248024B2/ja active Active
- 2014-12-08 HR HRP20141188A patent/HRP20141188T8/xx unknown
-
2015
- 2015-04-10 PH PH12015500806A patent/PH12015500806A1/en unknown
- 2015-04-22 US US14/692,948 patent/US9840562B2/en active Active
- 2015-06-29 IL IL239674A patent/IL239674A/en active IP Right Grant
-
2016
- 2016-05-26 IL IL245876A patent/IL245876A/en active IP Right Grant
-
2017
- 2017-01-20 JP JP2017008103A patent/JP6420379B2/ja active Active
- 2017-08-16 AR ARP170102289A patent/AR109355A2/es unknown
- 2017-11-08 US US15/807,351 patent/US10196452B2/en active Active
-
2018
- 2018-10-10 JP JP2018191343A patent/JP2019030313A/ja active Pending
-
2019
- 2019-01-11 US US16/245,816 patent/US20190135932A1/en not_active Abandoned
-
2021
- 2021-07-13 US US17/373,965 patent/US20220002428A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109355A2 (es) | Moléculas de unión al receptor ox40 humano | |
| CY1119647T1 (el) | Αντισωματα προσδεσης αλβουμινης και τμηματα προσδεσης αυτων | |
| AR070202A1 (es) | Anticuerpos anti- trkb mejorados | |
| ES2547463T3 (es) | Moléculas de unión a ILT3 y usos de las mismas | |
| CY1121536T1 (el) | Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης | |
| AR091069A1 (es) | Proteinas de union a antigeno dirigidas contra el receptor st2 | |
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| EA200970477A1 (ru) | Человеческие моноклональные антитела к btla и способы применения | |
| CO6231038A2 (es) | Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos | |
| AR083747A1 (es) | Anticuerpos anti-il-23 | |
| AR075882A1 (es) | Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7 | |
| EA200870020A1 (ru) | Человеческие моноклональные антитела против о8е | |
| CO6690759A2 (es) | Anticuerpos, fragmentos de unión o derivados de los mismos que se unen específicamente a la proteína 4-1 bb | |
| EA200800953A1 (ru) | Человеческие моноклональные антитела к cd70 | |
| EA200800229A1 (ru) | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) | |
| PE20080035A1 (es) | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina | |
| CR9969A (es) | Anticuerpos anti-globulomero ab, porciones de union a antigeno de estos, hibridomas correspondientes, acidos nucleicos, vectores, celulas huesped, metodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos | |
| AR038568A1 (es) | Anticuerpos anti-a beta y su uso | |
| EA201001223A1 (ru) | Стабилизированные белковые композиции | |
| CL2011001994A1 (es) | Anticuerpo antagonista que se une a la proteína ox40 humana; secuencia de adn que lo codifica; vector de clonación o de expresión que comprende dicho adn codificante; célula huésped que comprende dicho vector de clonación o expresión; proceso de producción de dicho anticuerpo; composición farmacéutica que comprende a dicho anticuerpo; uso médico de dicho anticuerpo; proteína de fusión que comprende a dicho anticuerpo. | |
| AR077111A1 (es) | Proteinas biespecificas tetravalentes de union a antigeno | |
| AR079336A1 (es) | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) | |
| EA201390146A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| PE20180042A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| EA200801621A1 (ru) | Антитела, направленные на her-3, и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |